{"id":452219,"date":"2021-03-08T03:03:10","date_gmt":"2021-03-08T08:03:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=452219"},"modified":"2021-03-08T03:03:10","modified_gmt":"2021-03-08T08:03:10","slug":"cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/","title":{"rendered":"Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing"},"content":{"rendered":"
\n

OKLAHOMA CITY, March 08, 2021 (GLOBE NEWSWIRE) — Cytovance\u00ae Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and gene therapy plasmid DNA (pDNA), announces a licensing opportunity for pDNA manufacturing. The Keystone Expression System\u00ae pDNA platform is an end-to-end solution for manufacturing GMP pDNA at scale in a manufacturer\u2019s own facility.<\/p>\n

\u201cThis is a great opportunity for biologics manufacturers to reduce the time and cost of getting their pDNA products to market through the use of our perfected manufacturing process,\u201d stated Matt Delaney, Vice President of Business Development and Marketing for Cytovance. \u201cOur platform is uniquely designed to process plasmids with low shear lysis and purification steps to produce high-quality, high-yield pDNA,\u201d Mr. Delaney added.<\/p>\n

License opportunities are currently available for either a 30L or 300L manufacturing scale. Each license includes end-to-end documentation including process descriptions, analytical standard operating procedures, critical equipment lists, facility layout, and much more. To ensure that pDNA manufacturing can begin quickly, Cytovance also offers hands-on process training, with our experts, at the manufacturer\u2019s facility.<\/p>\n

To learn more about Cytovance Biologics and the opportunity for pDNA Manufacturing Licensing, visit https:\/\/www.cytovance.com\/about-us<\/u><\/a>.<\/p>\n

\n About Cytovance\u00ae Biologics<\/strong>\n <\/p>\n

Cytovance\u00ae\u00a0Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that excels in the rapid and cost-effective development and manufacture of large molecule active pharmaceutical ingredients (APIs) from both mammalian cell culture and microbial fermentation such as monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines and other biological products including plasmid DNA and cell-based therapeutics. In addition to its clinical and commercial CGMP API manufacturing services, Cytovance offers well-integrated development services supporting the entire product lifecycle including cell line development, cell banking, microbial strain development, process and analytical development, and process characterization.\u00a0A centralized, responsive program management team coordinates all critical chemistry manufacturing and controls (CMC) activities for each client program around raw materials management, QC testing, ICH stability studies, and regulatory support.\u00a0 Our 140,000 sq. ft. state-of-the-art facilities in Oklahoma City are designed to meet U.S., EU, and other global regulatory standards.<\/p>\n

Cytovance offers deep industry expertise and unique customized services for the scale-up and CGMP manufacture of protein-based therapeutics; from early-stage pre-clinical development to commercial production, for both mammalian and microbial. Further information can be found at www.cytovance.com<\/u><\/a>.<\/p>\n

\n Media Contact:<\/strong>
\n
Jodie Gutkowski
Tel: 405-319-8309\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
E-mail: jgutkowski@cytovance.com<\/a><\/u><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

OKLAHOMA CITY, March 08, 2021 (GLOBE NEWSWIRE) — Cytovance\u00ae Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and gene therapy plasmid DNA (pDNA), announces a licensing opportunity for pDNA manufacturing. The Keystone Expression System\u00ae pDNA platform is an end-to-end solution for manufacturing GMP pDNA at scale in a manufacturer\u2019s own facility. \u201cThis is a great opportunity for biologics manufacturers to reduce the time and cost of getting their pDNA products to market through the use of our perfected manufacturing process,\u201d stated Matt Delaney, Vice President of Business Development and Marketing for Cytovance. \u201cOur platform is uniquely designed to process plasmids with low shear lysis and purification steps to produce high-quality, high-yield pDNA,\u201d Mr. Delaney … <\/p>\n

Continue reading “Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-452219","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCytovance Biologics now offering Licensing for Plasmid DNA Manufacturing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"OKLAHOMA CITY, March 08, 2021 (GLOBE NEWSWIRE) — Cytovance\u00ae Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and gene therapy plasmid DNA (pDNA), announces a licensing opportunity for pDNA manufacturing. The Keystone Expression System\u00ae pDNA platform is an end-to-end solution for manufacturing GMP pDNA at scale in a manufacturer\u2019s own facility. \u201cThis is a great opportunity for biologics manufacturers to reduce the time and cost of getting their pDNA products to market through the use of our perfected manufacturing process,\u201d stated Matt Delaney, Vice President of Business Development and Marketing for Cytovance. \u201cOur platform is uniquely designed to process plasmids with low shear lysis and purification steps to produce high-quality, high-yield pDNA,\u201d Mr. Delaney … Continue reading "Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-08T08:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MTgwNyM0MDQxMjU1IzIwODQ2ODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing\",\"datePublished\":\"2021-03-08T08:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\\\/\"},\"wordCount\":402,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MTgwNyM0MDQxMjU1IzIwODQ2ODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\\\/\",\"name\":\"Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MTgwNyM0MDQxMjU1IzIwODQ2ODQ=\",\"datePublished\":\"2021-03-08T08:03:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MTgwNyM0MDQxMjU1IzIwODQ2ODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MTgwNyM0MDQxMjU1IzIwODQ2ODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/","og_locale":"en_US","og_type":"article","og_title":"Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing - Market Newsdesk","og_description":"OKLAHOMA CITY, March 08, 2021 (GLOBE NEWSWIRE) — Cytovance\u00ae Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and gene therapy plasmid DNA (pDNA), announces a licensing opportunity for pDNA manufacturing. The Keystone Expression System\u00ae pDNA platform is an end-to-end solution for manufacturing GMP pDNA at scale in a manufacturer\u2019s own facility. \u201cThis is a great opportunity for biologics manufacturers to reduce the time and cost of getting their pDNA products to market through the use of our perfected manufacturing process,\u201d stated Matt Delaney, Vice President of Business Development and Marketing for Cytovance. \u201cOur platform is uniquely designed to process plasmids with low shear lysis and purification steps to produce high-quality, high-yield pDNA,\u201d Mr. Delaney … Continue reading \"Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-08T08:03:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MTgwNyM0MDQxMjU1IzIwODQ2ODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing","datePublished":"2021-03-08T08:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/"},"wordCount":402,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MTgwNyM0MDQxMjU1IzIwODQ2ODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/","name":"Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MTgwNyM0MDQxMjU1IzIwODQ2ODQ=","datePublished":"2021-03-08T08:03:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MTgwNyM0MDQxMjU1IzIwODQ2ODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MTgwNyM0MDQxMjU1IzIwODQ2ODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytovance-biologics-now-offering-licensing-for-plasmid-dna-manufacturing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=452219"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452219\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=452219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=452219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=452219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}